Use the hyperlinks, where available to access additional clinical trial information.
A Randomised Phase II Trial Comparing the Efficacy of Single-fraction or Multi-fraction SABR (Stereotactic Ablative Body Radiotherapy) With AteZolizumab in Patients With Advanced Triple nEgative Breast Cancer
Trans Tasman Radiation Oncology Group (TROG)
Other Non-Commercial Sponsor
Peter MacCallum Cancer Centre
Participants with triple negative breast cancer will be randomised to receive either SABR 20Gy in one fraction or 24 Gy in 3 fractions , they will then go onto receive atezolizumab for up to 24 months